Gynaecologic cancers, including ovarian, endometrial, and cervical malignancies, remain significant challenges in women’s health worldwide. Advances in early detection and ovarian cancer screening are reshaping clinical approaches to these diseases. Innovations from liquid biopsy technologies to AI in cancer detection have seen notable transformations in how clinicians approach diagnosis. This article examines the latest advances and their implications for clinical practice.
Globally, gynaecologic cancers account for over 1.4 million new cases annually, with ovarian, endometrial, and cervical cancers presenting distinct diagnostic challenges. While cervical cancer has seen mortality reductions through established screening programmes, ovarian cancer continues to be diagnosed at advanced stages in approximately 70% of cases, resulting in poor survival outcomes.*
Identifying these cancers at earlier stages remains central to improving survival rates. When ovarian cancer is identified at stage I, the five-year survival rate exceeds 90%. However, most patients are diagnosed at stage III or IV, when survival drops to approximately 30%, according to research published in Cancer Discovery*. Unlike cervical cancer, which benefits from established HPV-based screening, ovarian and endometrial cancers lack reliable population-wide screening methods.
The intersection of oncology and women’s health is now driving innovation in early detection. From non-invasive blood-based tests to HPV self-collection technologies, these advancements may improve diagnosis and patient outcomes when integrated into clinical practice. The following sections explore current developments across three areas: molecular diagnostics using blood and cervicovaginal samples, computational approaches to imaging and screening, and emerging considerations for clinical implementation.
Key topics covered in this article:
How do you see advances in early detection influencing the diagnosis and management of gynaecologic cancer in clinical practice? Share your perspective in the comments.
Liquid Biopsy Innovations for Ovarian and Endometrial Cancer
Liquid biopsy has emerged as a developing approach to gynaecologic cancer detection and early detection of ovarian and uterine malignancies, offering non-invasive analysis of tumour-derived cancer biomarkers in blood and other body fluids. Unlike traditional tissue biopsy, these methods can detect circulating tumour DNA (ctDNA), proteins, and other cellular components shed by cancer cells. A comprehensive review in the Journal of Experimental & Clinical Cancer Research outlines the translational framework for these technologies in gynaecologic oncology.*
Cell-Free DNA Fragmentomes for Ovarian Cancer
A 2025 study published in Cancer Discovery demonstrated that combining cell-free DNA (cfDNA) fragmentome analysis with protein cancer biomarkers could improve ovarian cancer screening across all stages with high accuracy.* The approach analysed patterns in cfDNA fragment lengths alongside traditional markers such as CA-125 and HE4, achieving strong diagnostic performance even in early-stage disease.
This multi-modal approach represents an advance over single-biomarker testing, offering clinicians a more comprehensive view of potential malignancy.
PapSEEK: Repurposing the Pap Test for Upper Gynaecologic Cancers
Researchers have developed PapSEEK, a test that examines cervical fluid samples for DNA mutations and chromosomal abnormalities associated with ovarian and uterine cancers. According to Ludwig Cancer Research, PapSEEK detected 81% of endometrial cancers and 33% of ovarian cancers, with no false positives among healthy controls.*
Using a Tao brush for sample collection, which extends further into the cervical canal, improved sensitivity to 93% for endometrial cancer and 45% for ovarian cancer. When combined with plasma testing, ovarian cancer detection increased to 63%.
While blood-based and cervicovaginal molecular diagnostics are expanding, imaging and computational tools are also redefining screening pathways.
AI in Cancer Detection and Self-Collection Technologies in Screening
AI in cancer detection and self-sampling technologies are changing gynaecologic cancer screening approaches, with potential to enhance both diagnostic accuracy and access to women’s health care.
AI-Enhanced Imaging and Diagnostics
Computational methods are reshaping gynaecologic oncology diagnostics. As highlighted in the FIGO Cancer Report 2025, innovations such as automated colposcopy analysis and advanced imaging algorithms for ovarian and uterine cancers have achieved high levels of accuracy, reducing diagnostic delays and enabling more personalised treatment.*
AI models are improving transvaginal ultrasound interpretation for endometrial cancer detection. Recent research demonstrated that AI algorithms could enhance accuracy in detecting endometrial cancer and atypical hyperplasia, exceeding traditional clinical assessment.*
For ovarian cancer screening, deep learning frameworks using preoperative laparoscopic images can now predict treatment outcomes and stratify patients based on prognosis. Machine learning algorithms applied to hysteroscopic images have demonstrated diagnostic accuracy of over 90% for endometrial cancer, compared to 80% for traditional methods.*
Self-Collection for HPV Testing- HPV self-collection represents one of the most significant recent advances in cervical cancer screening. The FDA approved self-collection in clinical settings in 2024, expanding access to screening for populations who may face barriers to traditional methods, as noted by NCI guidelines.*
In December 2025, the American Cancer Society updated its cervical cancer screening guidelines to include self-collection of vaginal samples for primary HPV testing as an acceptable option.* While clinician-collected cervical specimens remain preferred, self-collected samples now offer a validated alternative for patients who may otherwise skip screening.
Self-sampling technologies may be valuable for reaching underserved populations. The World Health Organization’s 90-70-90 initiative aims for 70% cervical cancer screening coverage by 2030, and HPV self-collection could contribute to achieving this goal. Diagnostics
The Future of Detection: Clinical Considerations
The convergence of liquid biopsy, AI in cancer detection, and self-sampling technologies is creating new possibilities for gynaecologic cancer early detection. However, translating these advances into clinical practice requires addressing several practical considerations.
Emerging blood-based tests aim to detect multiple cancer types from a single draw, including gynaecologic malignancies. These multi-cancer early detection (MCED) approaches combine multiple cancer biomarkers modalities, ctDNA methylation, fragmentation patterns, and protein markers to identify cancers at earlier stages.*
Future screening strategies may integrate gynaecologic cancer detection into routine women’s health visits. By analysing samples already collected for Pap smears or other purposes, clinicians could screen for ovarian and endometrial cancers without additional procedures. Frontiers in Oncology research highlights the potential of cervicovaginal fluid and uterine lavage as specimen sources.
The cost-effectiveness of novel screening technologies remains an open question. While liquid biopsy and AI-enhanced imaging show promise, their value relative to existing methods requires evaluation through health economic analyses. Primary care settings may face different implementation challenges than tertiary centres with specialised oncology services, and reimbursement pathways for emerging diagnostics are still evolving in many health systems.
As screening sensitivity increases, the risk of false positives also rises. This can lead to unnecessary follow-up procedures, patient anxiety, and healthcare costs. Clinicians will need clear protocols for managing positive results from novel screening tests, including guidance on confirmatory testing and appropriate referral pathways.
Many of the technologies discussed are at varying stages of clinical validation. While some, like HPV self-collection, have received regulatory approval and guideline endorsement, others remain investigational. Clinicians should consider the level of evidence supporting each approach when evaluating potential adoption. Large-scale prospective studies comparing novel methods to established ovarian cancer screening protocols will be essential for informing clinical guidelines.
Implementation in Different Care Settings
The feasibility of implementing new screening technologies may vary across care settings. Primary care practices may benefit from self-collection and point-of-care testing, while advanced imaging and liquid biopsy platforms may be more suited to specialist centres. Health systems will need to develop workflows that account for these differences while ensuring equitable access.
What are your observations on these developments in gynaecologic cancer care? Share your clinical perspectives in the comments below.
Are You a Healthcare Professional?
Did you enjoy this article?
Join our community of healthcare professionals to share your opinion
You Might Be Interested in:
Bridging Oncology and Women’s Health: Early Detection Innovations in Gynaecologic Cancers
New advances in oncology and women’s health highlight progress in detecting gynaecologic cancers, including cervical malignancies, using AI in cancer detection.
The Microbiome and Cancer: How Gut Health Influences Treatment Response
Once considered peripheral to cancer care, gut microbial ecosystems are now understood to influence immune activation, inflammation, and drug metabolism, all of which are critical to how gut health affects cancer therapy.
Are You an Oncologist or Haematologist?
What is your opinion on new technologies and advancements in chemotherapy, hormone therapy, immunotherapy, and targeted therapy? Join M3 today and share your opinion
latest posts
Genetic Risk Score May Help Predict Disease Severity in Inflammatory Bowel Disease
Danish study links higher Genetic Risk Score to more severe Inflammatory Bowel Disease, highlighting the impact of genetic predisposition.
Foundation AI Model Pre-Trained on MRI Data Shows Promise for Detecting Multiple Brain Disorders
Nature Neuroscience study introduces BrainIAC, an AI model using MRI data for detecting multiple brain disorders.
Understanding Cancer Genes: How DNA Mutations Drive Cancer Development
Explainer on Understanding Cancer Genes shows how DNA Mutations and genetic changes drive cancer development and inherited risk.
Join Today
Panel Members